Targeted Therapies and Pharmacologic Advances in Mucous Membrane Pemphigoid: A Comprehensive Review
Keywords:
Autoimmune Bullous Dermatoses, Mucous Membrane Pemphigoid, Cicatricial Pemphigoid, Pemphigoid Antibodies, Novel therapiesAbstract
Introduction: Mucous membrane pemphigoid (MMP) is a rare autoimmune bullous dermatosis which predominantly affects the mucous membranes and, occasionally, the skin. The exact pathogenesis of MMP remains unclear and should be considered as a unique phenomenon, which involves the formation of subepithelial blisters and fibrosis.
Objectives: This narrative review aimed to summarize the pharmacological agents which showed efficacy in the management of MMP but that are not included in the guidelines.
Methods: We conducted a search on Google Scholar, PubMed, and the Web of Science databases concerning articles published in English on the management of MMP between January 2000 and February 2025; all the sourced articles were full-text reviewed.
Results: We included 13 articles. The studied pharmacological agents are classified as immunosuppressive agents (leflunomide, sirolimus, daclizumab) and biologics (daclizumab, dupilumab, omalizumab, bevacizumab, aflibercept, cenegermin); the immunosuppressant leflunomide and the antimalarial agent hydroxychloroquine are also classified as disease-modifying antirheumatic drugs. Other pharmacological agents (colchicine, corticotropin, varenicline, lifitegrast) exert miscellaneous mechanisms.
Conclusion: Considering the severity of the condition, progressive fibrosis, and resistance to therapy, more research is required in relation to the pathogenesis of MMP and the efficacy and safety profile of novel pharmacological options. Pharmacological agents should provide the achievement and maintenance of remission with minimal adverse effects. A broader spectrum of pharmacological agents will allow a personalized approach and more alternatives, in particular for recalcitrant cases, failure of the previous therapy, and in patients with MMP and malignancy.
References
Rashid H, Lamberts A, Borradori L, et al. European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part I. J Eur Acad Dermatol Venereol. 2021;35(9):1750-1764. DOI: 10.1111/jdv.17397. PMID: 34245180.
Di Zazzo A, Cutrupi F, De Antoniis MG, et al. Tissue Remodeling in Ocular Mucous Membrane Pemphigoid. Invest Ophthalmol Vis Sci. 2023;64(15):17. DOI: 10.1167/iovs.64.15.17. PMID: 38095906.
Chan LS, Ahmed AR, Anhalt GJ, et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol. 2002;138(3):370-9. DOI: 10.1001/archderm.138.3.370. PMID: 11902988.
Santi CG, Gripp AC, Roselino AM, et al. Consensus on the treatment of autoimmune bullous dermatoses: bullous pemphigoid, mucous membrane pemphigoid and epidermolysis bullosa acquisita – Brazilian Society of Dermatology. An Bras Dermatol. 2019;94(2 Suppl 1):33-47. DOI: 10.1590/abd1806-4841.2019940207. PMID: 31166405.
Ujiie H, Iwata H, Yamagami J, et al. Japanese guidelines for the management of pemphigoid (including epidermolysis bullosa acquisita). J Dermatol. 2019;46(12):1102-1135. DOI: 10.1111/1346-8138.15111. PMID: 31646663.
Bedane C, Prost C, Ingen-Housz-Oro S, Joly P, Bernard P; Centres de référence des maladies bulleuses auto-immunes. Société Française de Dermatologie. Recommandations des centres de référence des maladies bulleuses auto-immunes pour le diagnostic et la prise en charge de la pemphigoïde cicatricielle [Mucous membrane pemphigoid. Guidelines for the diagnosis and treatment. Centres de référence des maladies bulleuses auto-immunes. Société Française de Dermatologie]. Ann Dermatol Venereol. 2011;138(3):259-63. French. DOI: 10.1016/j.annder.2011.01.014. PMID: 21397156.
Schmidt E, Rashid H, Marzano AV, Lamberts A, Di Zenzo G, Diercks GFH, et al. European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part II. J Eur Acad Dermatol Venereol. 2021;35(10):1926-1948. DOI: 10.1111/jdv.17395. PMID: 34309078.
Hofmann SC, Günther C, Böckle BC, et al. S2k Guideline for the diagnosis and treatment of mucous membrane pemphigoid. J Dtsch Dermatol Ges. 2022;20(11):1530-1550. Doi: 10.1111/ddg.14905. PMID: 36354061.
Elder MJ, Lightman S. The immunological features and pathophysiology of ocular cicatricial pemphigoid. Eye (Lond). 1994;8(Pt 2):196-9. DOI: 10.1038/eye.1994.45. PMID: 7958021.
Papaliodis GN, Chu D, Foster CS. Treatment of ocular inflammatory disorders with daclizumab. Ophthalmology. 2003;110(4):786-9. DOI: 10.1016/S0161-6420(02)01932-2. PMID: 12689903.
Razzaque MS, Ahmed BS, Foster CS, Ahmed AR. Effects of IL-4 on conjunctival fibroblasts: possible role in ocular cicatricial pemphigoid. Invest Ophthalmol Vis Sci. 2003;44(8):3417-23. DOI: 10.1167/iovs.02-1084. PMID: 12882790.
Saw VP, Offiah I, Dart RJ, et al. Conjunctival interleukin-13 expression in mucous membrane pemphigoid and functional effects of interleukin-13 on conjunctival fibroblasts in vitro. Am J Pathol. 2009;175(6):2406-15. DOI: 10.2353/ajpath.2009.090579. PMID: 19910508.
Wang Z, Liu X, Ni J, Qi Y, Song Z, Piao Y. Successful Treatment of Mucous Membrane Pemphigoid with Dupilumab: A Case Report. Acta Derm Venereol. 2024;104:adv40162. DOI: 10.2340/actadv.v104.40162. PMID: 39188088.
Raef HS, Elmariah SB. Successful Treatment of Brunsting-Perry Cicatricial Pemphigoid With Dupilumab. J Drugs Dermatol. 2021;20(10):1113-1115. DOI: 10.36849/JDD.6032. PMID: 34636516.
Corti L, Fanoni D, Venegoni L, Muratori S, Recalcati S, Berti E. Detection of IgE autoantibodies in mucous membrane pemphigoid and their association with disease severity. G Ital Dermatol Venereol. 2020;155(6):754-759. DOI: 10.23736/S0392-0488.18.06167-9. PMID: 30298707.
Yayli S, Pelivani N, Beltraminelli H, et al. Detection of linear IgE deposits in bullous pemphigoid and mucous membrane pemphigoid: a useful clue for diagnosis. Br J Dermatol. 2011;165(5):1133-7. DOI: 10.1111/j.1365-2133.2011.10481.x. PMID: 21711326.
Natsuga K, Nishie W, Shinkuma S, et al. Circulating IgA and IgE autoantibodies in antilaminin-332 mucous membrane pemphigoid. Br J Dermatol. 2010;162(3):513-7. DOI: 10.1111/j.1365-2133.2009.09508.x. PMID: 19751242.
Alexandre M, Bohelay G, Gille T, et al. Rapid Disease Control in First-Line Therapy-Resistant Mucous Membrane Pemphigoid and Bullous Pemphigoid with Omalizumab as Add-On Therapy: A Case Series Of 13 Patients. Front Immunol. 2022;13:874108. DOI: 10.3389/fimmu.2022.874108. PMID: 35514989.
Williams GP, Nightingale P, Southworth S, et al. Conjunctival Neutrophils Predict Progressive Scarring in Ocular Mucous Membrane Pemphigoid. Invest Ophthalmol Vis Sci. 2016;57(13):5457-5469. DOI: 10.1167/iovs.16-19247. PMID: 27760272.
Murthy S, Patzelt S, Künstner A, Busch H, Schmidt E, Sadik CD. Intravenous Ig Ameliorates Disease in a Murine Model of Anti-Laminin 332 Mucous Membrane Pemphigoid. J Invest Dermatol. 2024;144(12):2671-2681.e1. DOI: 10.1016/j.jid.2024.02.038. PMID: 38692406.
Sardana K, Sinha S, Sachdeva S. Colchicine in Dermatology: Rediscovering an Old Drug with Novel Uses. Indian Dermatol Online J. 2020 Sep 19;11(5):693-700. DOI: 10.4103/idoj.IDOJ_475_20. PMID: 33235833.
Robertson S, Martínez GJ, Payet CA, et al. Colchicine therapy in acute coronary syndrome patients acts on caspase-1 to suppress NLRP3 inflammasome monocyte activation. Clin Sci (Lond). 2016;130(14):1237-46. DOI: 10.1042/CS20160090. PMID: 27129183.
Fribourg E, Chuy V, Fenelon M, Catros S, Fricain JC. Is There a Role for Colchicine in the Treatment of Oral Mucous Membrane Pemphigoid? Oral Dis. 2025;31(4):1237-1240. DOI: 10.1111/odi.15193. PMID: 39497341.
Chaidemenos G, Sidiropoulos T, Katsioula P, Koussidou-Eremondi T. Colchicine in the management of mucous membrane pemphigoid. Dermatol Ther. 2011;24(4):443-5. DOI: 10.1111/j.1529-8019.2011.01438.x. PMID: 21910802.
Fox RI. Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin Arthritis Rheum. 1993;23(2):82-91. DOI: 10.1016/s0049-0172(10)80012-5. PMID: 8278823.
Morel M, DeGrazia T, Ward L, Behshad S, Kim HJ, Feldman R. Single Center Retrospective Study of Patients with Ocular Mucous Membrane Pemphigoid (MMP). Ocul Immunol Inflamm. 2022 ;30(1):256-261. DOI: 10.1080/09273948.2020.1783322. PMID: 32835566.
Guerrero JCS, Vincenzi K, Buñay PGP, et al. Brunsting-Perry Cicatricial Pemphigoid of the Scalp. IJCMCR. 2025;48(3):005. DOI: 10.46998/IJCMCR.2025.49.001210.
Misra DP, Gasparyan AY, Zimba O. Benefits and adverse effects of hydroxychloroquine, methotrexate and colchicine: searching for repurposable drug candidates. Rheumatol Int. 2020;40(11):1741-1751. DOI: 10.1007/s00296-020-04694-2. PMID: 32880032.
Sharma AN, Mesinkovska NA, Paravar T. Characterizing the adverse dermatologic effects of hydroxychloroquine: A systematic review. J Am Acad Dermatol. 2020;83(2):563-578. DOI: 10.1016/j.jaad.2020.04.024. PMID: 32289395.
Smichowski AM, Caputo VD, Romeo C, Rivero E, Morales NS, Casado G. Ocular cicatricial pemphigoid: Methotrexate as an initial treatment? Reumatol Clin (Engl Ed). 2022;18(1):30-32. DOI: 10.1016/j.reumae.2020.10.003. PMID: 34088654.
Boedeker CC, Termeer CC, Staats R, Ridder GJ. Cicatricial pemphigoid in the upper aerodigestive tract: diagnosis and management in severe laryngeal stenosis. Ann Otol Rhinol Laryngol. 2003;112(3):271-5. DOI: 10.1177/000348940311200314. PMID: 12656421.
Kaltwasser JP, Behrens F. Leflunomide: long-term clinical experience and new uses. Expert Opin Pharmacother. 2005;6(5):787-801. DOI: 10.1517/14656566.6.5.787. PMID: 15934905.
Askanase AD, Furie RA. A Narrative Review of Repository Corticotropin Injection for the Treatment of Systemic Lupus Erythematosus. Adv Ther. 2022;39(7):3088-3103. DOI: 10.1007/s12325-022-02160-y. PMID: 35641860.
Sharon Y, Anesi SD, Martinez CE, Huang AJW, Foster CS, Chu DS. Repository Corticotropin Injection as an Alternative Treatment for Refractory Ocular Mucous Membrane Pemphigoid. Cornea. 2022;41(1):45-51. DOI: 10.1097/ICO.000000000000277. PMID: 34050065.
Abbott KS, Palestine AG, Hauswirth SG, Gregory DG, Patnaik JL, Reddy AK. Treatment of Ocular Surface Disease in Ocular Cicatricial Pemphigoid. Ocul Immunol Inflamm. 2024;32(10):2479-2485. Doi: 10.1080/09273948.2024.2413892. PMID: 39383489.
Surico PL, Kaufman AR, Lin J, Dehghani S, Dana R. Corneal Superficial Plaque Formation After Recombinant Human Nerve Growth Factor Use in a Patient With Neurotrophic Keratopathy and Limbal Stem Cell Deficiency From Mucous Membrane Pemphigoid. Cornea. 2024;43(7):899-902. DOI: 10.1097/ICO.0000000000003442. PMID: 38015976.
Morelon E, Mamzer-Bruneel MF, Peraldi MN, Kreis H. Sirolimus: a new promising immunosuppressive drug. Towards a rationale for its use in renal transplantation. Nephrol Dial Transplant. 2001;16(1):18-20. Doi: 10.1093/ndt/16.1.18. PMID: 11208987.
Atzori L, Conti B, Zucca M, Pau M. Bullous pemphigoid induced by m-TOR inhibitors in renal transplant recipients. J Eur Acad Dermatol Venereol. 2015;29(8):1626-30. DOI: 10.1111/jdv.12662. PMID: 25174440.
Hwang S, Kuo SC. Corneal perforation in ocular cicatricial pemphigoid: A CARE-compliant case report. Medicine (Baltimore). 2021;100(51):e28266. DOI: 10.1097/MD.0000000000028266. PMID: 34941105.
Stan C, Diaconu E, Hopirca L, Petra N, Rednic A, Stan C. Ocular cicatricial pemphigoid. Rom J Ophthalmol. 2020;64(2):226-230. PMID: 32685792.
Wirta D, Lipsky W, Toyos M, et al. Recombinant human nerve growth factor (cenegermin) for moderate-to-severe dry eye: phase II, randomized, vehicle-controlled, dose-ranging trial. BMC Ophthalmol. 2024;24(1):290. DOI: 10.1186/s12886-024-03564-w. PMID: 39020305.
Zhong M, Gadek TR, Bui M, et al. Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye. ACS Med Chem Lett. 2012;3(3):203-6. DOI: 10.1021/ml2002482. PMID: 24900456.
Kianfar N, Dasdar S, Camilleri MJ, Lehman JS. Mucous membrane pemphigoid and malignancy: Systematic review and meta-analysis of 1429 patients. JAAD Reviews. 2024;1:82-92. DOI:10.1016/j.jdrv.2024.07.003.
Shi L, Li X, Qian H. Anti-Laminin 332-Type Mucous Membrane Pemphigoid. Biomolecules. 2022;12(10):1461. DOI: 10.3390/biom12101461. PMID: 36291670.
Nonnast E, Mira E, Mañes S. The role of laminins in cancer pathobiology: a comprehensive review. J Transl Med. 2025;23(1):83. DOI: 10.1186/s12967-025-06079-0. PMID: 39825429.
Patzelt S, Schmidt E. Autoimmunity against laminin 332. Front Immunol. 2023;14:1250115. DOI: 10.3389/fimmu.2023.1250115. PMID: 37638011.
Li X, Pas HH, Qian H, et al. Potential correlation between anti-laminin 332 autoantibodies and malignant tumours in anti-BP180-type mucous membrane pemphigoid. Clin Exp Dermatol. 2024;49(9):1075-1076. DOI: 10.1093/ced/llae124. PMID: 38634807.
Syal A, Lott DG, Karle WE. Radiation-Induced Laryngeal Mucous Membrane Pemphigoid. Ann Otol Rhinol Laryngol. 2023;132(10):1261-1264. DOI: 10.1177/00034894221139121. PMID: 36433793.
Kotnik N, Diercks GFH, Jalving H, et al. Pemphigoid diseases as immune-related adverse effect following immune checkpoint inhibitors: A clinical case series of a diverse spectrum. JAAD Case Rep. 2025;61:100-106. DOI: 10.1016/j.jdcr.2025.03.021. PMID: 40538786.
Nouri A, Olbrich H, Schmidt E, Ludwig RJ, Curman P. Increased risk of skin cancers in mucous membrane pemphigoid: a large-scale matched cohort study of 117 million US individuals. Front Med (Lausanne). 2025;12:1585167. DOI: 10.3389/fmed.2025.1585167. PMID: 40248080.
Eckembrecher DG, Eckembrecher FJ, Camacho I, et al. A review of heart transplant immunosuppressants and nonmelanoma skin cancer. Arch Dermatol Res. 2023;315(9):2491-2503. DOI: 10.1007/s00403-023-02646-x. PMID: 37256379.
Gu SL, Nath S, Markova A. Safety of Immunomodulatory Systemic Therapies Used in the Management of Immune-Related Cutaneous Adverse Events. Pharmaceuticals (Basel). 2023;16(11):1610. DOI: 10.3390/ph16111610. PMID: 38004475.
Fojnica A, Gromilic Z, Ali Mohamed YA, Akhtar S, Vranic S. The potential role of cyclosporine A in cancer treatment: a comprehensive literature review. Contemp Oncol (Pozn). 2024;28(4):271-282. DOI: 10.5114/wo.2024.147009. PMID: 39935757.
Benjanuwattra J, Chaiyawat P, Pruksakorn D, Koonrungsesomboon N. Therapeutic potential and molecular mechanisms of mycophenolic acid as an anticancer agent. Eur J Pharmacol. 2020;887:173580. DOI: 10.1016/j.ejphar.2020.173580. PMID: 32949604.
Nam HJ, Kim YE, Moon BS, et al. Azathioprine antagonizes aberrantly elevated lipid metabolism and induces apoptosis in glioblastoma. iScience. 2021;24(3):102238. DOI: 10.1016/j.isci.2021.102238. PMID: 33748720.
Goodman RS, Johnson DB, Balko JM. Corticosteroids and Cancer Immunotherapy. Clin Cancer Res. 2023;29(14):2580-2587. DOI: 10.1158/1078-0432.CCR-22-3181. PMID: 36648402.
Huang S, Anderson HJ, Lee JB. Paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome: Part II. Diagnosis and management. J Am Acad Dermatol. 2024;91(1):13-22. DOI: 10.1016/j.jaad.2023.08.084. PMID: 37714216.
Antiga E, Bech R, Maglie R, et al. S2k guidelines on the management of paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2023;37(11):2378-2379. DOI: 10.1111/jdv.19489. PMID: 36965110.
Tarnowietzki E, Peters T, Kraus L, Schmidt E, Scharffetter-Kochanek K. Remission of Anti-laminin 332 Mucous Membrane Pemphigoid Associated with Non-small Cell Lung Cancer after Therapy with Rituximab and Intravenous Immunoglobulin. Acta Derm Venereol. 2020;100(17):adv00301. DOI: 10.2340/00015555-3621. PMID: 32852563.
Gitin A, Porta AD, Bisbee E, Braunlich K, Motaparthi K. Anti-laminin 332 mucous membrane pemphigoid in a young woman treated with rituximab. Dermatol Online J. 2022;28(4). DOI: 10.5070/D328458517. PMID: 36259856.
Hügel R, Lang A, Lhotta K, et al. Anti-laminin 332 mucous membrane pemphigoid with laryngeal involvement – adjuvant treatment with immunoadsorption and rituximab. J Dtsch Dermatol Ges. 2018;16(7):897-900. DOI: 10.1111/ddg.13569. PMID: 29927519.
Chou WH, McGregor B, Schmidt A, et al. Cyclophosphamide-associated bladder cancers and considerations for survivorship care: A systematic review. Urol Oncol. 2021;39(10):678-685. DOI: 10.1016/j.urolonc.2021.05.017. PMID: 34134927.
Hirunsatitpron P, Hanprasertpong N, Noppakun K, Pruksakorn D, Teekachunhatean S, Koonrungsesomboon N. Mycophenolic acid and cancer risk in solid organ transplant recipients: Systematic review and meta-analysis. Br J Clin Pharmacol. 2022;88(2):476-489. DOI: 10.1111/bcp.14979. PMID: 34240462.
Gordon H, Biancone L, Fiorino G, et al. ECCO Guidelines on Inflammatory Bowel Disease and Malignancies. J Crohns Colitis. 2023;17(6):827-854. DOU: 10.1093/ecco-jcc/jjac187. PMID: 36528797.
Peng Y, Tao Y, Zhang Y, Wang J, Yang J, Wang Y. CD25: A potential tumor therapeutic target. Int J Cancer. 2023;152(7):1290-1303. DOI: 10.1002/ijc.34281. PMID: 36082452.
Ceesay MM, Matutes E, Taylor GP, et al. Phase II study on combination therapy with CHOP-Zenapax for HTLV-I associated adult T-cell leukaemia/lymphoma (ATLL). Leuk Res. 2012;36(7):857-61. DOI: 10.1016/j.leukres.2011.12.004. PMID: 22209076.
Iglesias-Escudero M, Arias-González N, Martínez-Cáceres E. Regulatory cells and the effect of cancer immunotherapy. Mol Cancer. 2023;22(1). DOI: 10.1186/s12943-023-01714-0. PMID: 36739406.
Ali ES, Mitra K, Akter S, et al. Recent advances and limitations of mTOR inhibitors in the treatment of cancer. Cancer Cell Int. 2022;22(1):284. DOI: 10.1186/s12935-022-02706-8. PMID: 36109789.
Rubicondo M, Ciardelli G, Mattu C, Tuszynski JA. Recent advancements in colchicine derivatives: Exploring synthesis, activities, and nanoformulations for enhanced therapeutic efficacy. Drug Discovery Today. 2025;30(3):104312. DOI: 10.1016/j.drudis.2025.104312. PMID: 39947582.
Yeh JJ, Liw PX, Wong YS, et al. The effect of colchicine on cancer risk in patients with immune-mediated inflammatory diseases: a time-dependent study based on the Taiwan’s National Health Insurance Research Database. Eur J Med Res. 2024;29(1):245. DOI: 10.1186/s40001-024-01836-1. PMID: 38649928.
Guo S, Wang L, Bu D, Liu F. Tumors in the setting of dupilumab use: A review of the literature. World Allergy Organ J. 2024;18(1):101006. DOI: 10.1016/j.waojou.2024.101006. PMID: 39758935.
Ferreira C, Freitas E, Torres T. Efficacy and safety of dupilumab in a patient with metastatic clear cell renal cell carcinoma. J Int Med Res. 2024;52(11):3000605241297551. DOI: 10.1177/03000605241297551. PMID: 39575618.
Deeks ED, Lamb YN. Cenegermin: A Review in Neurotrophic Keratitis. Drugs. 2020;80(5):489-494. DOI: 10.1007/s40265-020-01289-w. PMID: 32185680.
Hayes DF. Bevacizumab treatment for solid tumors: boon or bust? JAMA. 2011;305(5):506-8. DOI: 10.1001/jama.2011.57. PMID: 21285431.
Vultaggio A, Petrella MC, Tomao F, et al. The anti-IgE monoclonal antibody omalizumab as adjuvant treatment in desensitization to carboplatin in patients with ovarian cancer. Gynecol Oncol Rep. 2021;38:100880. DOI: 10.1016/j.gore.2021.100880. PMID: 34926761.
Neumann R, Tauber J, Foster CS. Remission and recurrence after withdrawal of therapy for ocular cicatricial pemphigoid. Ophthalmology. 1991;98(6):858-62. DOI: 10.1016/s0161-6420(91)32209-7. PMID: 1866137.
Tofern S, Fähnrich A, Künzel S, et al. 075 Inhibition of phosphodiesterase-4 significantly decreases oral mucosa lesions in experimental anti-laminin 332 mucous membrane pemphigoid. Journal of Investigative Dermatology. 2019;139(9):S227. DOI: 10.1016/j.jid.2019.07.078.
Ghorbanalipoor S, Emtenani S, Parker M, et al. Cutaneous kinase activity correlates with treatment outcomes following PI3K delta inhibition in mice with experimental pemphigoid diseases. Front Immunol. 2022;13:865241. DOI: 10.3389/fimmu.2022.865241. PMID: 36248903.
Patzelt S, Pigors M, Steenbock H, et al. Increased Fibrosis in a Mouse Model of Anti-Laminin 332 Mucous Membrane Pemphigoid Remains Unaltered by Inhibition of Aldehyde Dehydrogenase. Front Immunol. 2022;12:812627. DOI: 10.3389/fimmu.2021.812627. PMID: 35197965.
Ahadome SD, Abraham DJ, Rayapureddi S, et al. Aldehyde dehydrogenase inhibition blocks mucosal fibrosis in human and mouse ocular scarring. JCI Insight. 2016;1(12):e87001. DOI: 10.1172/jci.insight.87001. PMID: 27699226.
Kumari S, Bhol KC, Rehman F, Foster CS, Ahmed AR. Interleukin 1 components in cicatricial pemphigoid. Role in intravenous immunoglobulin therapy. Cytokine. 2001;14(4):218-24. DOI: 10.1006/cyto.2001.0877. PMID: 11448121.
Letko E, Bhol K, Colon J, Foster CS, Ahmed AR. Biology of interleukin-5 in ocular cicatricial pemphigoid. Graefes Arch Clin Exp Ophthalmol. 2002;240(7):565-9. DOI: 10.1007/s00417-002-0497-4. PMID: 12136288.
Suelves AM, Zhao TZ, Siddique SS, Foster CS. Profile of local interleukin expression in a cohort of ocular cicatricial pemphigoid patients. Invest Ophthalmol Vis Sci. 2012;53(13):8112-7. DOI: 10.1167/iovs.11-9322. PMID: 23081979.
Caproni M, Calzolari A, Giomi B, Santucci M, Ficarra G, Fabbri P. IL-4, IL-5, TGF-beta1 and IFN-gamma mRNAs detected by a new in situ amplification system in cicatricial pemphigoid. Exp Dermatol. 2002;11(5):421-7. DOI: 10.1034/j.1600-0625.2002.110505.x. PMID: 12366695.
Karakioulaki M, Eyerich K, Patsatsi A. Advancements in Bullous Pemphigoid Treatment: A Comprehensive Pipeline Update. Am J Clin Dermatol. 2024;25(2):195-212. DOI: 10.1007/s40257-023-00832-1. PMID: 38157140.
Khalid SN, Khan ZA, Ali MH, Almas T, Khedro T, Raj Nagarajan V. A blistering new era for bullous pemphigoid: A scoping review of current therapies, ongoing clinical trials, and future directions. Ann Med Surg (Lond). 2021;70:102799. DOI: 10.1016/j.amsu.2021.102799. PMID: 34540212.
Zhang J, Wang SH, Zuo YG. Paradoxical phenomena of bullous pemphigoid induced and treated by identical biologics. Front Immunol. 2023;13:1050373. DOI: 10.3389/fimmu.2022.1050373. PMID: 36685489.
Tanaka A, Fujimura Y, Fuke S, Izumi K, Ujiie H. A case of bullous pemphigoid developing under treatment with benralizumab for bronchial asthma. J Dermatol. 2023;50(9):1199-1202. DOI: 10.1111/1346-8138.16811. PMID: 37122191.
Published
Issue
Section
License
Copyright (c) 2025 Vera Nikolaevna Busol, Nikita Victorovich Kudryashov
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.
How to Cite
Share
